Conferences
ESMO 2023: Discussant: TAR-210 & SunRISe-1
October 23, 2023
ESMO 2023: Discussant – ABACUS-2, NEMIO, EV-103 (Cohort-L)
October 23, 2023
ESMO 2023: Discussant - MEDI5752 (Volrustomig) for 1st Line Advanced Clear Cell Renal Cell Carcinoma & TIDE-A
October 23, 2023
ESMO 2023: TIDE-A: Phase II Study of Avelumab plus Intermittent Axitinib in Previously Untreated Patients with mRCC
October 23, 2023
ESMO 2023: Treatment Patterns Among Novel Hormonal Therapy-experienced Patients with mCRPC
October 23, 2023
ESMO 2023: Exposure-Safety Analyses of Talazoparib in Combination of Enzalutamide in Patients with mCRPC in TALAPRO-2 Trial
October 23, 2023
ESMO 2023: 177Lu-PSMA-617 in Pre- and Post-Taxane mCRPC Setting: Results from the Phase II IRST-185.03 Clinical Trial
October 23, 2023
ESMO 2023: Real-World Overall Survival with Enzalutamide and Abiraterone Acetate in Patients with Chemotherapy-Naïve mCRPC
October 23, 2023
ESMO 2023: The Impact of Baseline PSMA PET/CT versus CT on Outcomes of Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer Patients
October 22, 2023
ESMO 2023: PSMA-Alpha Targeted Radionuclide Therapy with or without Prior PSMA-Beta Targeted Radionuclide Therapy
October 22, 2023